Editorial
Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugs

https://doi.org/10.1016/j.drugpo.2015.07.008Get rights and content

Section snippets

Conclusions

This is an exciting era for the field of HCV. As newer IFN-free DAA agents become available, strategies to address HCV infection among PWID will need to be integrated into existing foundations for prevention and health care for PWID, in partnership with the affected community and with a commitment to tackling stigma and discrimination associated with injecting drug use and HCV. However, as we move forward, and as the themed papers in this issue highlight, it will be important to consider how

Financial support

The Kirby Institute and the Centre for Social Research in Health are funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. JG is supported by a National Health and Medical Research Council Career Development Fellowship. GD is supported by a National Health and Medical Research Council Practitioner Research Fellowships.

Disclosures

JG is a consultant/advisor and has received research grants from Abbvie, Bristol Myers Squibb, Gilead Sciences and Merck. GD is a consultant/advisor and has received research grants from Abbvie, Bristol Myers Squibb, Gilead, Merck, Janssen and Roche. PB is consultant/advisor and has received research grants from Abbvie, Bristol Myers Squibb, Gilead, Janssen and Merck.

References (30)

Cited by (0)

View full text